Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BI/NAP1/027 strain caused CDI in only 1 patient.
|
25782900 |
2015 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared multilocus variable-number tandem-repeat analysis (MLVA) and macrorestriction endonuclease analysis using pulsed-field gel electrophoresis (PFGE) to determine their utility to identify clusters of Clostridium difficile infection (CDI) among 91 isolates of PCR ribotype 027 (NAP1, for North American pulsed-field type 1) from nine hospitals (and 10 general practitioners associated with one institution) in England.
|
18216211 |
2008 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gold standard was the toxigenic culture for the diagnosis of CDI and PCR ribotyping for the identification of the NAP1/027/BI strain.
|
21487764 |
2011 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infection with the epidemic NAP-1 strain was not associated with metronidazole failure in endemic CDI.
|
19081526 |
2008 |
Central Diabetes Insipidus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The increased incidence and severity of Clostridium difficile infection (CDI) are thought to result partly from the emergence of the hypervirulent BI/NAP1/027 strain.
|
29174729 |
2018 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months.
|
28501926 |
2017 |
Central Diabetes Insipidus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clostridium difficile infection (CDI) is an increasing cause of nosocomial diarrhoea worldwide, which has been partly attributed to the emergence of hypervirulent strains including C. difficile BI/NAP1/ribotype 027 and BK/NAP7/ribotype 078.
|
30052178 |
2018 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whole genome sequencing of CA-CDI isolates confirmed that NAP 1-like pulsotypes are commonplace in CA-CDI.
|
30170546 |
2018 |
Central Diabetes Insipidus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Over 75 % of CDIs with NAP1 was hospital-acquired, and more often proceeded with generalized infection (p < 0.05).
|
24213847 |
2014 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NAP1 strain did not increase disease severity, mortality, or recurrence in this study, although the incidence of NAP1-positive healthcare associated-CDI was low.
|
28645479 |
2017 |
Central Diabetes Insipidus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Colonized patients contribute to transmission, but CDI cases are more likely linked to other infected patients than colonized patients in this cohort with high rates of the NAP1/027/ST1 strain, highlighting the importance of local prevalence of virulent strains in determining transmission dynamics.
|
29846557 |
2019 |
Central Diabetes Insipidus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clostridium difficile infection (CDI) has been increasing in incidence and severity in recent years, coincident with the spread of a "hypervirulent" strain, REA type BI (ribotype 027, PFGE NAP 1).
|
19755166 |
2009 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent outbreaks of CDI have been associated with the emergence of hypervirulent strains, such as NAP1/BI/027, many strains of which also produce a third toxin, binary toxin (CDTa and CDTb).
|
28125650 |
2017 |